BMS joins Octant’s $80M financing and signs on as a drug discovery partner

[cafead]

via Octant Bio’s synthetic biology approach to drug discovery is making progress, and the preclinical biotech has raised $80 million in Series B financing to continue the journey. The company added Bristol Myers Squibb as an investor and collaborator in the search for new immunology drugs.

article source